Plecanatide vs BI 456906
Head-to-head comparison of Plecanatide (Plecanatide) and BI 456906 (BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Plecanatide | BI 456906 |
|---|---|---|
| Category | Gastrointestinal | Weight Management |
| Full Name | Plecanatide | BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | Approx. 1620 Da | N/A |
| Half-Life | Local intestinal action; systemic half-life not clinically meaningful | Approximately 1 week |
| Amino Acids | 16 | N/A |
| Typical Dose | 3 mg once daily | Trial-dependent; weekly SC dosing |
| Route | Oral | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 350 | 10 |
| Research Status | Clinical | Clinical |
Plecanatide Benefits
- ✓improves-stool-frequency
- ✓supports-fluid-secretion
- ✓may-reduce-constipation
- ✓local-gut-action
BI 456906 Benefits
- ✓weight reduction
- ✓improved glucose control
- ✓lower liver-fat burden
- ✓enhanced satiety
Plecanatide Dosing
3 mg PO daily|take with or without food|avoid when dehydrated
BI 456906 Dosing
once-weekly subcutaneous injection|stepwise titration|ongoing maintenance phase
Plecanatide Side Effects
- ⚠diarrhea
- ⚠abdominal-discomfort
- ⚠nausea
BI 456906 Side Effects
- ⚠nausea
- ⚠abdominal discomfort
- ⚠diarrhea
Research Overview
Plecanatide
Clinical trials show plecanatide improves constipation outcomes with a generally favorable tolerability profile. Like linaclotide, it acts locally in the intestinal lumen via GC-C signaling rather than systemic hormone effects.
BI 456906
Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.